TARDBP and Alzheimer disease: The results presented here, as well as other evidence, indicate that LBD, TDP-43 pathology, and WMR, as common comorbidities with autosomal dominant and early-onset sporadic AD, should be considered when planning clinical trials with such subjects as they may increase variability in response rates.